NZ724912A - Transmucosal drug delivery devices for use in chronic pain relief - Google Patents

Transmucosal drug delivery devices for use in chronic pain relief

Info

Publication number
NZ724912A
NZ724912A NZ724912A NZ72491212A NZ724912A NZ 724912 A NZ724912 A NZ 724912A NZ 724912 A NZ724912 A NZ 724912A NZ 72491212 A NZ72491212 A NZ 72491212A NZ 724912 A NZ724912 A NZ 724912A
Authority
NZ
New Zealand
Prior art keywords
drug delivery
chronic pain
transmucosal drug
delivery devices
pain relief
Prior art date
Application number
NZ724912A
Other versions
NZ724912B2 (en
Inventor
Niraj Vasisht
Andrew Finn
Original Assignee
Biodelivery Sciences Int Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biodelivery Sciences Int Inc filed Critical Biodelivery Sciences Int Inc
Publication of NZ724912A publication Critical patent/NZ724912A/en
Publication of NZ724912B2 publication Critical patent/NZ724912B2/en

Links

Abstract

Provided are uses of a transmucosal drug delivery device comprising buprenorphine in the manufacture of a medicament for treating chronic pain with a low incidence of adverse effects. The device comprises a bioerodable mucoadhesive layer comprising buprenorphine disposed in a buffered polymeric diffusion environment, wherein the polymeric diffusion environment is a buffered environment having a pH of between about 4 and about 6, and a backing layer buffered to a pH of between about 4.0 and about 4.8 and that does not include an opioid antagonist.
NZ724912A 2011-12-21 2012-12-21 Transmucosal drug delivery devices for use in chronic pain relief NZ724912B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161578755P 2011-12-21 2011-12-21
US61/578,755 2011-12-21
NZ62714512 2012-12-21

Publications (2)

Publication Number Publication Date
NZ724912A true NZ724912A (en) 2018-06-29
NZ724912B2 NZ724912B2 (en) 2018-10-02

Family

ID=

Similar Documents

Publication Publication Date Title
MX2009000745A (en) Transmucosal delivery devices with enhanced uptake.
EA033256B1 (en) Abuse-resistant two-layered devices for delivery of buprenorphine
CL2011000967A1 (en) Dosage form comprising tapentadol in a slow release formulation, microcrystalline cellulose, polyvinyl alcohol, ethyl cellulose, colloidal silicon dioxide, sodium stearyl fumarate, optionally with pregabalin, and an opioid antagonist selected from naloxone, naltrexone or nalmefene, used as an analgesic .
EP2563450A4 (en) Device for delivery of rheumatoid arthritis medication
MX2014000129A (en) Drug combinations and uses in treating a coughing condition.
MX2012007933A (en) Topical transdermal dexmedetomidine compositions and methods of use thereof.
MX2013007622A (en) A combination of an opioid agonist and an opioid antagonist in the treatment of parkinson's disease.
EA201400737A1 (en) DELIVERY SYSTEM ON THE BASIS OF A PELLET SET WITH IMMEDIATE release of an ACTIVE SUBSTANCE
WO2014153385A3 (en) Methods of treating metabolic disorders
MX2018010755A (en) Montelukast transmucosal film.
MX2016006279A (en) Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome.
WO2012082821A3 (en) Melanoma treatments
WO2013083826A3 (en) Glp-1 agonists
NZ724912A (en) Transmucosal drug delivery devices for use in chronic pain relief
MX2020007860A (en) Combination treatments for opioid crisis.
IL285091A (en) Transmucosal drug delivery devices for use in chronic pain relief
TR201803744T4 (en) Compositions containing naltrexone for use in the treatment of scleroderma.
MX357376B (en) Pharmaceutical composition for use against inflammation and pain.
IN2014DN09359A (en)
UA96455C2 (en) Transmucosal delivery devices with enhanced uptake
IN2013MU02852A (en)
UA55479U (en) Method for preventing and treating miscarriage in patients with drug addiction and urogenital infections
UA33217U (en) Method for treating chronic dermatosis
UA57850U (en) Method for treating leiomyoma of uterus in patients of child-bearing age
UA52855U (en) Method for complex nanotechnological detoxification in opioid addiction

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 21 DEC 2019 BY DAVIES COLLISON CAVE PTY LTD

Effective date: 20181005

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 DEC 2020 BY COMPUTER PACKAGES INC

Effective date: 20191203

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 DEC 2021 BY COMPUTER PACKAGES INC

Effective date: 20201201

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 DEC 2022 BY COMPUTER PACKAGES INC

Effective date: 20211130

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 DEC 2023 BY COMPUTER PACKAGES INC

Effective date: 20221130